<DOC>
	<DOCNO>NCT02482753</DOCNO>
	<brief_summary>This study evaluate efficacy safety Chidamide combination exemestane postmenopausal patient hormone-receptor positive advanced breast cancer .</brief_summary>
	<brief_title>Trial Chidamide Combination With Exemestane Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>This study include two part : ( 1 ) Part A , open-label design , 20 patient enrol receive 30 mg Chidamide BIW 25 mg exemestane QD . The main object part A evaluate pharmacokinetic pharmacodynamic profile Chidamide combination exemestane . ( 2 ) Part B , randomize double-blinded design , 328 patient assign randomly 2:1 ratio experiment group ( 30 mg Chidamide BIW + 25 mg exemestane QD ) control group ( placebo BIW + 25 mg exemestane QD ) , evaluate efficacy safety Chidamide combination exemestane patient locally advance metastatic estrogen receptor-positive breast cancer progress endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . 18 ~ 75 year old , postmenopausal woman ; 2 . Histological cytological confirmation hormone receptorpositive [ estrogen receptor ( ER ) positive progesterone receptor ( PgR ) positive negative ] breast cancer ; 3 . Disease progression recurrence least one endocrine therapy ( either advanced/metastatic setting adjuvant setting ) ; 4 . ≤4 prior therapy ( either advanced/metastatic setting adjuvant setting ) , patient may receive one prior chemotherapy ; 5 . The disease condition inoperable , stage III stage IV , least one measurable lesion simple bone metastases measurable lesion ; 6 . Last prior therapy interval : ( ) last treatment endocrine therapy , interval must ≥ 2 week ; ( b ) last treatment chemotherapy therapy , interval must ≥ 4 week ; 7 . Eastern Cooperative Oncology Group Performance Status : 0~1 ; 8 . Absolute neutrophil count ≥ 1.5×109 / L , platelet count ≥ 100×109 / L , hemoglobin ≥ 90 g/L ; 9 . Life expectancy ≥ 3 month ; 10 . Have sign inform consent . 1 . Patients known central nervous system ( CNS ) metastases history CNS metastases , leptomeningeal disease ; 2 . Patients human epidermal growth factor receptor2 ( Her2 ) positive ; 3 . Patients previously receive treatment exemestane ; 4 . Patients receive radiotherapy ≤ 4 week prior study entry ; 5 . Patients measurable lesion ( except simple bone metastasis ) , pleural pericardial effusion , ascites , et al ; 6 . Patients uncontrolled significant cardiovascular disease , include : 1 . Myocardial infarction ( &lt; last 12 month ) 2 . Uncontrolled angina ( &lt; last 6 month ) 3 . Congestive heart failure ( &lt; last 6 month ) , Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % prior study entry 4 . History significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , TdP ) 5 . History significant QT interval prolongation , Corrected QT Interval ( QTc ) &gt; 450 m prior study entry 6 . History cerebrovascular accident 7 . Symptomatic coronary heart disease require treatment agent 7 . The size fluid area detect cardiac ultrasonography cavum pericardium ≥10mm diastolic period ; 8 . History organ transplantation ; 9 . Patients recover clinically relevant toxicity grade 1 due prior therapy ; 10 . Patients clinical significant gastrointestinal abnormality , e.g. , unable swallow , chronic diarrhea , ileus , would interfere ingestion , transportation absorption oral agent ; 11 . Active infection [ Suffered active infection bacteria , virus , fungi , mycobacteria , parasite , infection ( exclude nail bed fungal infection ) , require intravenous antibiotic therapy , antiviral therapy , hospitalization due significant infection event ] , persistent fever within 14 day prior study entry ; 12 . Patients organ surgery &lt; 6 week prior study entry ; 13 . Abnormal liver function [ total bilirubin &gt; 1.5×upper limit normal ( &gt; 3×upper limit normal case Gilbert syndrome ) ; Transaminases ( ALT , AST ) &gt; 2.5×upper limit normal ( &gt; 5x upper limit normal patient liver metastasis ) , abnormal renal function ( serum creatinine &gt; 1.5×upper limit normal ) ; 14 . Patients prior invasive malignancy exception curativelytreated basal cell squamous cell carcinoma skin cervical carcinoma situ , unless receive curative treatment document evidence recurrence past five year ; 15 . Any mental cognitive disorder , would interfere ability understand inform consent document operation compliance study ; 16 . Patients currently enrol another investigational drug study , complete within 4 week prior study entry , exception patient overall survival followup ; 17 . Any condition inappropriate study opinion investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chidamide</keyword>
	<keyword>breast cancer</keyword>
	<keyword>exemestane</keyword>
	<keyword>Estrogen Receptor</keyword>
</DOC>